Janus Henderson Group PLC Kinnate Biopharma Inc. Transaction History

Janus Henderson Group PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$7.73 - $17.99 $990,846 - $2.31 Million	-128,182 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$16.5 - $25.48 $19,057 - $29,429	1,155 Added 0.91%	128,182 $2.27 Million
Q3 2021 Nov 16, 2021	SELL	$17.81 - $24.87 $8.47 Million - $11.8 Million	-475,709 Reduced 78.92%	127,027 $2.92 Million
Q2 2021 Aug 16, 2021	SELL	$22.19 - $31.55 $4.38 Million - $6.23 Million	-197,538 Reduced 24.68%	602,736 $13.5 Million
Q1 2021 May 17, 2021	SELL	$26.99 - $40.0 $148,310 - $219,800	-5,495 Reduced 0.68%	800,274 $24.3 Million
Q4 2020 Feb 16, 2021	BUY	$36.35 - $45.25 $29.3 Million - $36.5 Million	805,769 New	805,769 $30.4 Million

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.